20230804-招银国际-Product_sales_soared_in_2Q_with_improved_cost_efficiency_7页_1mb

BeiGene (BGNE US) Earnings Summary

Product Sales Performance

• Q2 2023 Revenue: $554 million, marking a 35% quarter-over-quarter increase (+82% year-over-year).
• Zanubrutinib: Sales reached $308 million, driven by strong U.S. adoption (+46% QoQ or 139% YoY); US sales specifically rose 61% QoQ to $234 million, primarily in CLL/SLL patients.
• Tislelizumab: Generated $150 million in sales (+30% QoQ or 43% YoY), bolstered by NRDL price cuts and expanded hospital listings.

Financial Highlights

• Margin Improvements: Gross margin expanded to 82.7% compared to 80.1%, largely due to high-margin zanubrutinib growth.
• Expense Control: SG&A ratio dropped from 80% to 71%, and R&D ratio fell from 100% to 76%, demonstrating positive operating leverage.
• Net Loss: Q2 net loss of $381 million, with $3.5 billion in cash reserves supporting financial stability.

R&D and Innovation Progress

• Clinical Trials: Sonrotoclax (Bcl-2) entered a Phase 3 study, with BTK-CDAC targeting pivotal trials in 2024; synergistic partnerships aim to drive pipeline advancements.
• Pipeline Targets: Company plans to bring 15+ molecules to clinical trials by mid-2025, focusing on best-in-class therapies in haematology and oncology.
• Key Milestones: Zanubrutinib is expected U.S. FDA approval for follicular lymphoma in 2024; tislelizumab seeks 2H2023 US approval for ESCC.

Future Outlook and Valuation

• Growth Projections: Zanubrutinib sales forecasted at $1.2 billion YoY for FY2023; financial efficiency expected to drive margin increases in future years.
• Analyst Recommendation: Maintain "BUY" with a target price of $291.47 (+39.3% upside from current $209.24).
• Market Position: Anticipated market share growth for BTK inhibitors and leadership in PD-(L)1 antibody market, supported by expanding partnerships.

Observations

The report highlights robust revenue growth, improved profitability, and a commitment to innovation, positioning BeiGene for sustainable expansion in global markets, despite challenges like regulatory hurdles and competition.